Back to results
US 2021/0228709 A1Published application
Coronavirus vaccine formulations
AssigneeNovavax, Inc.
InventorsGale SMITH, Michael J. MASSARE, Jing-Hui TIAN
Life of this patent
Estimating the term…
Abstract
Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
Claims27
An immunogenic composition comprising:
- (a) a non-naturally occurring sudden acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (CoV S) glycoprotein, wherein the CoV S glycoprotein consists of two modifications compared to a native CoV S glycoprotein wherein
- (i) the first modification is an inactivated furin cleavage site consisting of mutation of amino acids 669-672 to QQAQ (SEQ ID NO:
- 7);
- and
- (ii) the second modification is mutation of amino acids 973 and 974 to proline;
- wherein the amino acids are numbered according to SEQ ID NO:
- 2;
- (b) a saponin adjuvant;
- and
- (c) a pharmaceutically acceptable buffer.
7 more elements
Dependencies are inferred from the claim text.